Sigyn Therapeutics explores NASDAQ merger, establishes clinical pathway
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/8/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives
January 15, 2026 11:01 AM ESTSAN DIEGO, CA - January 15, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, today released the following shareholder update authored by Chief Executive Officer, Jim Joyce.
Dear Shareholders and Interested Parties,
Cardiovascular disease is the #1 cause of death worldwide. The primary aim of treatment is to reduce major adverse cardiovascular events (MACE).
The leading class of drugs to treat cardiovascular disease are statins, which reduce the incidence of MACE by approximately 25%. In contrast, blood purification therapies (lipoprotein apheresis) can... More
